Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 36,100 shares, a decrease of 80.5% from the February 28th total of 184,900 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily volume of 99,800 shares, the short-interest ratio is presently 0.4 days.

Creative Medical Technology Stock Performance

CELZ stock opened at $2.21 on Friday. The stock has a 50-day moving average price of $3.78 and a two-hundred day moving average price of $3.24. Creative Medical Technology has a 1 year low of $1.92 and a 1 year high of $6.90. The stock has a market cap of $3.86 million, a PE ratio of -0.58 and a beta of 1.70.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC bought a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.